---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019014"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:34:05.770349+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MAIA reports 30-month (912-day) survival for a Phase 2 NSCLC patient; ESMO posters presented

## Summary
- One third-line NSCLC patient on ateganosine (THIO) survived 30 months/912 days as of Sep 17, 2025.
- THIO-101 Phase 2 trial evaluates ateganosine + cemiplimab in checkpoint-inhibitor-resistant advanced NSCLC.
- New Phase 3 THIO-104 trial compares ateganosine+ICI vs chemotherapy in ICI-resistant NSCLC.
- Posters presented at ESMO 2025 in Berlin; full posters available on MAIA website.
- CEO states >2-year survival is a clear signal of ateganosine's efficacy in eliminating NSCLC tumors.

## SEC filing metadata
- accession: 0001493152-25-019014
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225019014/0001493152-25-019014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225019014/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019014
- JSON: https://secwatch.observer/filing/0001493152-25-019014.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.